Novocure (NVCR) said Monday that the phase 3 ENGOT-ov50 / GOG-3029 / INNOVATE-3 clinical trial of Tumor Treating Fields together with paclitaxel in patients with platinum-resistant ovarian cancer did not meet its primary endpoint of overall survival at the final analysis.
In Monday pre-market trade, NVCR was trading at $17.51 down $12.26 or 41.18%.
According to the company, Patients randomized to receive Tumor Treating Fields or TTFields therapy plus paclitaxel demonstrated a median OS of 12.2 months versus a median overall survival of 11.9 months in patients treated with paclitaxel alone. Consistent with previously reported studies, TTFields therapy was well-tolerated with no added systemic toxicities.
Novocure stated that it will work with investigators to share the full results with the scientific community.
For More Such Health News, visit rttnews.com
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.